Stoke Therapeutics, Inc. - STOK STOCK NEWS

Stoke Therapeutics (Nasdaq: STOK) announced progress in its STK-001 trials for Dravet syndrome, expecting to complete Phase 1/2a studies in 2023 and initiate Phase 3 in 2024. The company will deliver safety and efficacy data from various dosing cohorts throughout 2023. Financially, Stoke reported revenue of $12.4 million for 2022, a net loss of $101.1 million, and increased R&D expenses totaling $77.8 million. Stoke's cash reserves stand at $230.2 million, projected to fund operations until the end of 2025, supporting the advancement of STK-001 and STK-002.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology firm focused on treating severe diseases by enhancing protein expression through RNA-based therapies. The company will participate in two upcoming investor conferences: the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 p.m. ET, and the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023, at 3:20 p.m. ET. Live webcasts and replays will be accessible on Stoke's investor website. Stoke is known for its proprietary TANGO technology and is developing treatments for conditions like Dravet syndrome and autosomal dominant optic atrophy (ADOA). More details can be found on their website.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology firm focused on upregulating protein expression with RNA-based therapies, will present at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 4:20 p.m. ET. This presentation will be in a fireside chat format and will be webcast live, available on Stoke's website for 30 days post-event. Stoke's lead compound, STK-001, targets Dravet syndrome, a severe genetic epilepsy, while STK-002 is under development for autosomal dominant optic atrophy. The company is headquartered in Bedford, Massachusetts, with operations in Cambridge, Massachusetts.

Stoke Therapeutics (NASDAQ: STOK) announced key milestones for 2023, focusing on its STK-001 therapy for Dravet syndrome. The company expects to complete Phase 1/2a studies this year to initiate a Phase 3 program in 2024. Additional safety data from the ongoing 45mg and 70mg dose cohorts is anticipated in mid and late 2023, respectively. As of September 30, 2022, Stoke had $252.2 million in cash, sufficient to fund operations until 2025. The firm is also advancing STK-002 for autosomal dominant optic atrophy (ADOA) towards clinical trials.

Nuvig Therapeutics, a biopharma company focused on autoimmune diseases, appointed Julie Anne Smith as CEO and Board member. With over 20 years in the life sciences sector, she has previously led biotech firms through drug development. Pamela Conley transitions to Chief Scientific Officer, having co-founded the company. Smith's leadership comes as Nuvig's lead program progresses towards IND-enabling activities. Nuvig aims to develop novel therapies to restore immune function without broad immunosuppression.

Stoke Therapeutics, Inc. (Nasdaq: STOK) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. ET. The presentation will discuss the company’s innovative RNA-based medicines aimed at addressing severe diseases through upregulating protein expression. A live audio webcast will be accessible via the Investors & News section on Stoke’s website, with a replay available for 30 days post-event. Stoke is recognized for its proprietary TANGO approach and ongoing clinical trials for STK-001 in Dravet syndrome, as well as STK-002 for optic nerve disorders.

Stoke Therapeutics has reported promising interim results from clinical studies of STK-001, showing a 55% median reduction in convulsive seizure frequency among patients treated with three doses of 45mg. All but one of the patients showed a positive response. The treatment was well-tolerated with mild to moderate adverse events reported due to the study drug. Data from the ongoing SWALLOWTAIL study indicates sustained reductions in seizure frequency and improved non-seizure related measures, marking potential progress in the treatment of Dravet syndrome.

Stoke Therapeutics (Nasdaq: STOK) announced that seven abstracts on Dravet syndrome will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting in Nashville, Tennessee, from December 2-6. The abstracts include findings from the Phase 1/2a studies, MONARCH and ADMIRAL, highlighting significant reductions in seizure frequency with the investigational drug STK-001. The company aims to develop STK-001 as the first disease-modifying therapy for Dravet syndrome, targeting the underlying genetic cause of this severe epilepsy.

Stoke Therapeutics (Nasdaq: STOK) reported encouraging interim results from ongoing Phase 1/2a studies of STK-001, a treatment for Dravet syndrome, showing a 55% median reduction in convulsive seizure frequency with three doses of 45mg. The drug was well-tolerated, with 74% of patients experiencing reduced seizure frequency. As of September 30, 2022, the company had $252.2 million in cash, funding operations into 2025. The company plans to report more data in 2023 and has received FDA Rare Pediatric Disease Designation for STK-001.